GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
Subjects(RVK)
  • 1
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 11 ( 2022-1-11)
    Abstract: Cancer is the second leading cause of death in Armenia. Over the past two decades, the country has seen a significant rise in cancer morbidity and mortality. This review aims to provide up-to-date info about the state of cancer control in Armenia and identify priority areas of research. The paper analyzes published literature and local and international statistical reports on Armenia and similar countries to put numbers into context. While cancer detection, diagnosis, and treatment are improving, the prevalence of risk factors is still quite high and smoking is widespread. Early detection rates are low and several important screening programs are absent. Diagnosis and treatment methods are not standardized; there is a lack of treatment accessibility due to insufficient government coverage and limited availability of essential medicines. Overall, there is room for improvement in this sector, as research is limited and multidisciplinary approaches to the topic are rare.
    Type of Medium: Online Resource
    ISSN: 2234-943X
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2022
    detail.hit.zdb_id: 2649216-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Thoracic Oncology, Elsevier BV, Vol. 18, No. 4 ( 2023-04), p. 402-409
    Type of Medium: Online Resource
    ISSN: 1556-0864
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    detail.hit.zdb_id: 2223437-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e15058-e15058
    Abstract: e15058 Background: Over the past few years PD-1/PD-L1 pathway blockade through immune checkpoint inhibitors appeared to be an effective treatment approach in advanced lung cancer. The current study aims to investigate the utilization of immunotherapy for lung cancer management purposes in Armenia. Methods: For this retrospective, hospital-based cohort study census sampling method was approached. Data was collected on all the patients who were diagnosed with stage III and IV lung cancer and passed treatment in the departments of Adult Solid Tumors in Hematology Center after prof. Yeolyan and Institute of Surgery after Mikaelyan from 01.05.2019 till 12.01.2020. The time period was selected based on the initiation of PD-L1 testing in Armenia. The prevalence of non-small cell (NSCLC) and small cell (SCLC) lung cancer was calculated. The patients’ PD-L1 testing performance, subsequent immunotherapy utilization, and developed adverse effects were evaluated. Results: According to the hospital-based data, during the mentioned time period 60 patients diagnosed with stage III and IV lung cancer received treatment in the two units. In the cohort, the patients’ median age was 65,5 years (range 46 – 88). The male-to-female ratio was 5.6. The prevalence of NSCLC and SCLC was 61.7% and 28.3% respectively. At the time of follow-up on 10.02.2020, 74.4% of NSCLC patients and 64.7% of SCLC patients were alive. Of the 43 NSCLC subjects, only 11 were checked for the PD-L1 status. Among them, 7 were determined to be PD-L1 positive and 5 of them received immunotherapy. For SCLC patients PD-L1 status wasn’t checked. Of 17 SCLC patients, only one has received immunotherapy. Overall only one case of immunotherapy related adverse effect was observed (severe rash and pruritus). At the time of follow-up, one of the six patients who underwent immunotherapy was dead. Conclusions: The presented data demonstrate a lack of PD-L1 test performance and underutilization of immunotherapy treatment. In the future, it is recommended to perform a nationwide study on the current topic to assess the immune checkpoint inhibitors impact on the survival rates of advanced lung cancer patients.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  Journal of Clinical Oncology Vol. 38, No. 15_suppl ( 2020-05-20), p. e12586-e12586
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e12586-e12586
    Abstract: e12586 Background: Breast cancer (BC) is the most common malignancy among the women in Armenia (AM). Currently there is a knowledge gap regarding the morphology distribution of the BC in AM. Methods: The data on patients with BC diagnosed in 2015-2016 in the pathology lab “Davidyants Labs” in AM were retrospectively reviewed. Pts with Her2+ results by IHC were excluded from the study, due to unavailability to perform FISH or CISH analyses. Overall 361 pathology reports were evaluated. Results: The median age was 54 years; range [19-82]. Histopathological subtypes were defined for 305 pts, from which lobular carcinoma 57.4% of cases (175/305), ductal carcinoma 26.9% (82/305), mucinous carcinoma 2.6% (8/305), mixed type carcinoma (lobular and ductal) 2.6% (8/305), DCIS 2% (n = 6/305), non specified carcinoma 2% (6/305), medullary carcinoma 1% (n = 3/305) and others 5.6% (17/305). Within the cohort 8.5% (23/270) were grade 1, 65.9% grade 2 (178/270); 25.6% grade 3 (n = 69/270). Vascular or lymphatic invasion was present in 59.5% (50/84) and 64.7% (55/85), respectively. Staging distribution, based on pT pN data for 92 pts who went to primary surgery, was: 0 stage 7.6% (7/92), I stage 22.8% (21/92), II stage 41.3% (38/92), III stage 28.3% (26/92). Staging distribution based on ypT ypN data for 27 pts who went to surgery after neoadjuvant chemo was 0 stage 25.9% (7/27), I stage 18.5% (5/27), II stage 29.6% (8/27), III stage 25.9% (7/27). ER and PR were defined for 244 patients. ER positive 89.8% (219/244) of cases, PR pos. 73% (178/244), ER/PR pos. 72.5% (177/244) cases. Her receptor was defined for 237 patients. Her3+ 16.9% (40/237); Her2+ 12.7% (30/237); Her1+ 38% (90/237); Her0 32.5% (n = 77/237). We could not evaluate Her2+ status by FISH or CISH, so these results were excluded from the analysis. Ki67 was low (≤20) in 42.1% (101/240) of cases and high ( 〉 20) in 57.9% (139/240). Within the group Luminal A type was 41.4% (84/203); Luminal B 32.5% (66/203); Her positive 19.7% (40/203) and triple negative 6.4% (13/203). p53 and perineural invasion (Pn) was present in 32% (16/50) and 52% (26/50), respectively. Tumor leukocyte infiltration was determined for 16 patients. Leukocyte infiltration was positive in 43.7% (7/16) cases, negative in 25% (4/16) cases, minimal in 31.3% cases (5/16). Conclusions: BC in Armenian women presents with different epidemiological characteristics in comparison with other ethnicities. Lobular type BC is the most frequent type among Armenian women, however, differential diagnosis between lobular/ductal carcinomas was done without IHC (E-Cadherin), which rises the need for further studies on that regard.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e16251-e16251
    Abstract: e16251 Background: Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, pancreatic cancer is on the 12th place by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the last 12 years. Methods: For this retrospective hospital-based study we have collected data from three oncology centers in Armenia: “Muratsan” Hospital of Yerevan State Medical University, “Miqaelyan institute of surgery” and “Hematology center after prof. Yeolyan”. The information about patients with pancreatic cancer who were treated at these centers during 01/01/2010 - 01/01/2022 period was collected from the medical records. Log- rank test and Kaplan-Meier curves were used for survival analysis. Cox regression analysis was done for identification of main prognostic factors. Results: 70 patients with pancreatic cancer were involved in the final analysis. From them 44.3% were female. Median age at diagnosis was 63 years. Median follow up time was 10,5 months (range 2-146). 11,4% of patients had stage I-II, 27,1% stage III, 58,6% stage IV cancer. The main independent prognostic factor for overall survival (OS) was tumor grade, while TNM stage was not significant. 23% of patients were alive before study end date. Median OS was 12 months (range 2-146 months). Median overall survival was 35 months in stage I-II, 11 months in stage III and 11 months in stage IV. In stage I-III pancreatic cancer patients, those who had undergone surgery (44.4%) lived significantly longer (35 vs 11 months, p=0.011). 38.6% of patients received chemotherapy with Gemcitabine plus Capecitabine regimen, while 41.4% with FOLFIRINOX regimen. No significant difference in survival was found between these groups (11 vs 13 months, p=0.35). Conclusions: As our results has shown survival of pancreatic cancer patients in Armenia is dismal, not exceeding 1 year. Hopefully further research in the field and new treatment modalities will improve the situation.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. e16042-e16042
    Abstract: e16042 Background: Gastric cancer (GC) is a major health issue in Armenia, with late diagnosis in almost 80% of cases leading to poor outcomes. The study aims to assess the real-world experience of treating GC in Armenia and identify factors affecting survival. Methods: This retrospective study assessed the real-world experience of treating GC patients in Armenia from 05.2010 to 05.2022. The data were extracted from medical records of 3 major oncology centers. The factors analyzed in this study included TNM stage, grade, age, histology, Lauren type, and the treatment modality used. Univariate and multivariate Cox regression analyses were performed to determine the potential factors affecting survival. Results: A total of 216 patients with GC were included in the study, with a median age of 61 years (range 18-80 years) and an equal male-to-female ratio. The most common histology was adenocarcinoma (82.4%), followed by signet ring cell carcinoma (10.2%) and mucinous carcinoma (5.6%). The majority of patients were diagnosed with either stage 3 (42%) or stage 4 (39.4%), while 18.5% had stage 2 disease. The median overall survival (OS) was 43.7 mths for patients with stage 2 disease, 31.5 mths for stage 3, and 15.2 mths for stage 4, respectively. Patients who underwent surgery (gastrectomy with resection of all metastatic lesions or just gastrectomy) for stage 4 disease had improved median OS compared to those who did not (20.5 vs 11.2 mths, respectively (p=0.002)). Patients with stage 2-3 GC receiving perioperative chemotherapy (20%) had a better median OS that was not reached, compared to 34 months for those receiving solely adjuvant chemotherapy (80%) (p=0.008). The univariate and multivariate Cox regression analysis showed that the TNM stage was the only significant prognostic factor (p 〈 0.001) for survival, while grade, age, histology, and Lauren type were not significant. Only 9.4% of patients with stage 4 GC were tested for MSI status, and 33% for Her2. Among them just few eligible patients received treatment with targeted therapy or immunotherapy, mostly incompletely and over a few cycles. Conclusions: The results of this study emphasize the importance of early diagnosis and choice of treatment in improving survival outcomes for patients with GC in Armenia. The disease stage at diagnosis was the only significant prognostic factor for survival. In patients with stage 2-3 GC perioperative chemotherapy leads to better survival than adjuvant therapy alone; however, the study found that more than 80% of patients were treated with surgery upfront. The discrepancy may be due to patients being initially referred to surgeons rather than medical oncologists, leading to a lower proportion of patients receiving perioperative treatment. The limited use of targeted and immunotherapeutic agents, due to their high cost and limited accessibility, is a significant barrier to improving survival outcomes for patients with GC in Armenia.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 19 ( 2019-09), p. S268-
    Type of Medium: Online Resource
    ISSN: 2152-2650
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2019
    detail.hit.zdb_id: 2540998-0
    detail.hit.zdb_id: 2193618-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2020
    In:  Journal of Elasticity Vol. 140, No. 1 ( 2020-07), p. 79-93
    In: Journal of Elasticity, Springer Science and Business Media LLC, Vol. 140, No. 1 ( 2020-07), p. 79-93
    Type of Medium: Online Resource
    ISSN: 0374-3535 , 1573-2681
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2020
    detail.hit.zdb_id: 2015283-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Elsevier BV ; 2014
    In:  Journal of Mathematical Analysis and Applications Vol. 420, No. 2 ( 2014-12), p. 1744-1761
    In: Journal of Mathematical Analysis and Applications, Elsevier BV, Vol. 420, No. 2 ( 2014-12), p. 1744-1761
    Type of Medium: Online Resource
    ISSN: 0022-247X
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2014
    detail.hit.zdb_id: 1468566-8
    detail.hit.zdb_id: 2954-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Institute of Electrical and Electronics Engineers (IEEE) ; 2018
    In:  IEEE Transactions on Network and Service Management Vol. 15, No. 3 ( 2018-9), p. 961-975
    In: IEEE Transactions on Network and Service Management, Institute of Electrical and Electronics Engineers (IEEE), Vol. 15, No. 3 ( 2018-9), p. 961-975
    Type of Medium: Online Resource
    ISSN: 1932-4537 , 2373-7379
    Language: Unknown
    Publisher: Institute of Electrical and Electronics Engineers (IEEE)
    Publication Date: 2018
    detail.hit.zdb_id: 2156349-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...